RXC004
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for RXC004, covering 2025-01-29 to 2025-04-16. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) [Phase 2]